Eagle Pharmaceuticals Debt/Equity Ratio 2013-2023 | EGRX

Eagle Pharmaceuticals debt/equity ratio from 2013 to 2023. Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

Eagle Pharmaceuticals Debt/Equity Ratio 2013-2023 | EGRX

Eagle Pharmaceuticals debt/equity ratio from 2013 to 2023. Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$196.7B
Stryker (SYK)$142.8B
Boston Scientific (BSX)$132.8B
EssilorLuxottica (ESLOY)$110.9B
Medtronic (MDT)$105.8B
Haleon (HLN)$44.2B
Lonza Group Ag (LZAGY)$43.1B
GE HealthCare Technologies (GEHC)$37.1B
ResMed (RMD)$35B
Terumo (TRUMY)$29.6B
Koninklijke Philips (PHG)$24.2B
Zimmer Biomet Holdings (ZBH)$21.2B
Insulet (PODD)$18.9B
Baxter (BAX)$15.5B
Smith & Nephew SNATS (SNN)$11.2B
BellRing Brands (BRBR)$10B
Bio-Rad Laboratories (BIO)$9.4B
Demant (WILYY)$8.3B
Lantheus Holdings (LNTH)$6.5B
Haemonetics (HAE)$4.1B
Prestige Consumer Healthcare (PBH)$4.1B
ICU Medical (ICUI)$4B
Perrigo (PRGO)$3.7B
Envista Holdings (NVST)$3.4B
Shandong Weigao Medical Polymer (SHWGF)$3B
GN Store Nord (GNNDY)$2.9B
QuidelOrtho (QDEL)$2.8B
Neogen (NEOG)$2.6B
LeMaitre Vascular (LMAT)$2.3B
Green Thumb Industries (GTBIF)$1.7B